Serum Adiponectin Relates to Shortened Overall Survival in Men with Squamous Cell Esophageal Cancer Treated with Preoperative Concurrent Chemoradiotherapy: A Pilot Study

Background The convergence of nutritional, genetic, and inflammatory factors plays a significant role in the pathophysiology of squamous cell esophageal cancer (SCEC). The parameters of inflammation, indices of nutritional status, and adipocyte-derived hormones such as leptin, adiponectin, and resistin have been shown to be prognostic factors in some gastrointestinal and pancreatic cancers. Material/Methods Forty-two patients with SCEC were subjected to a multimodal regimen of concurrent neoadjuvant chemoradiotherapy (CRT) followed by surgery. We retrospectively analyzed the impact of pretreatment values of serum leptin, adiponectin, resistin, soluble leptin receptor, C-reactive protein, TNF alpha, leukocytes, and indices of nutritional status (BMI, plasma total protein, albumin, cholesterol, and triacylglycerols) on overall survival (OS). Results Univariate analysis revealed significant a negative correlation between OS and serum adiponectin (p=0.027), and a positive relationship was found between serum albumin (p=0.002), cholesterol (p=0.049) level, and OS. In multivariate analysis, only the trend (p=0.086) for negative serum adiponectin association with the OS was observed. Conclusions In men with SCEC treated by neoadjuvant concurrent CRT and esophagectomy, high pretreatment level of serum adiponectin was associated with shorter OS while the serum albumin and cholesterol were associated with longer OS.

[1]  A. Sonnenberg,et al.  Risk Factors in the Development of Esophageal Adenocarcinoma , 2013, The American Journal of Gastroenterology.

[2]  G. Lippi,et al.  The role of resistin in colorectal cancer. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[3]  M. Zemanova,et al.  Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. , 2012, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[4]  D. Fang,et al.  MicroRNA and its roles in esophageal cancer , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[5]  K. Lee,et al.  Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia , 2012, Journal of Korean medical science.

[6]  PhD Christophe Mariette MD,et al.  Surgery in Esophageal and Gastric Cancer Patients: What is the Role for Nutrition Support in your Daily Practice? , 2012, Annals of Surgical Oncology.

[7]  I. Ulman-Włodarz,et al.  Adiponectin to leptin index as a marker of endometrial cancer in postmenopausal women with abnormal vaginal bleeding: an observational study. , 2012, Neuro endocrinology letters.

[8]  V. Tutino,et al.  Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. , 2011, Anticancer research.

[9]  Mary T. Brinkoetter,et al.  Leptin in human physiology and pathophysiology. , 2011, American journal of physiology. Endocrinology and metabolism.

[10]  L. Feldman,et al.  IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[11]  A. Vasku,et al.  Relationship of resistin levels with endometrial cancer risk. , 2011, Neoplasma.

[12]  T. Zima,et al.  Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. , 2011, Neoplasma.

[13]  M. Wong,et al.  Associations between adipokines and obesity-related cancer. , 2011, Frontiers in bioscience.

[14]  D. Gupta,et al.  Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.

[15]  Qian-chun Yu,et al.  Klf4 overexpression activates epithelial cytokines and inflammation-mediated esophageal squamous cell cancer in mice. , 2010, Gastroenterology.

[16]  B. Melichar,et al.  Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience. , 2010, Hepato-gastroenterology.

[17]  E. Nowakowska-Zajdel,et al.  Leptin and its receptors in obese patients with colorectal cancer. , 2010, Journal of biological regulators and homeostatic agents.

[18]  T. Matsuda,et al.  Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer , 2010, Cancer science.

[19]  H. Takeda,et al.  Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. , 2010, World journal of gastroenterology.

[20]  Chien‐An Sun,et al.  Adipocytokine resistin and breast cancer risk , 2010, Breast Cancer Research and Treatment.

[21]  L. Petruzelka,et al.  Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[22]  T. Lawrence,et al.  The resolution of inflammation and cancer. , 2010, Cytokine & growth factor reviews.

[23]  M. Stampfer,et al.  A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. , 2010, Clinical chemistry.

[24]  I. Oda,et al.  Adipocytokines and squamous cell carcinoma of the esophagus , 2010, Journal of Cancer Research and Clinical Oncology.

[25]  Yan Wang,et al.  Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma , 2009, Lipids in Health and Disease.

[26]  C. Mantzoros,et al.  Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D G Altman,et al.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.

[28]  Serap Yıldırım,et al.  Serum adiponectin levels in patients with esophageal cancer. , 2008, Japanese journal of clinical oncology.

[29]  T. Krechler,et al.  Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. , 2009, Neoplasma.

[30]  M. Sok,et al.  Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer , 2009, Wiener klinische Wochenschrift.

[31]  C. Mantzoros,et al.  Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study , 2009, Cancer Causes & Control.

[32]  C. Mantzoros,et al.  Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study , 2009, Cancer Causes & Control.

[33]  E. Karapanagiotou,et al.  The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). , 2008, Lung cancer.

[34]  H. Parving,et al.  Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[35]  G. Fantuzzi Adiponectin and inflammation: consensus and controversy. , 2008, The Journal of allergy and clinical immunology.

[36]  M. Lazar,et al.  Adipokines and the peripheral and neural control of energy balance. , 2008, Molecular endocrinology.

[37]  T. Kadowaki,et al.  The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS , 2008, FEBS letters.

[38]  C. Mantzoros,et al.  Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. , 2007, The American journal of clinical nutrition.

[39]  D. Rose,et al.  Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. , 2007, Endocrine-related cancer.

[40]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[41]  V. Gebski,et al.  AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP. SURVIVAL BENEFI TS FROM NEOADJUVANT CHEMORADIOTHERAPY OR CHEMOTHERAPY IN OESOPHAGEAL CARCINOMA: A META-ANALYSIS , 2007 .

[42]  S. Jee,et al.  White Blood Cell Count and the Risk of Colon Cancer , 2006, Yonsei medical journal.

[43]  E. Surmacz,et al.  Leptin and cancer , 2006, Journal of cellular physiology.

[44]  I. Shimon,et al.  Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients , 2006, Cancer.

[45]  H. Nagawa,et al.  Plasma adiponectin and gastric cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  T. Erlinger,et al.  WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  M. Coleman,et al.  EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  K. Cianflone,et al.  Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[49]  J. Bełtowski Adiponectin and resistin--new hormones of white adipose tissue. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[50]  C. McArdle,et al.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer , 2003, The British journal of surgery.

[51]  Joanna D. Holbrook,et al.  Resistin is expressed in human macrophages and directly regulated by PPARγ activators , 2003 .

[52]  Cai Li,et al.  Generation of Soluble Leptin Receptor by Ectodomain Shedding of Membrane-spanning Receptors in Vitro and in Vivo * , 2002, The Journal of Biological Chemistry.

[53]  A. Ozet,et al.  Low Serum Leptin Level in Colon Cancer Patients without Significant Weight Loss , 2002, Tumori.

[54]  D. Carter TNM Classification of Malignant Tumors , 1998 .

[55]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.